# A First in Human Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics Effects of OC514

> **NCT05264038** · PHASE1 · COMPLETED · sponsor: **Oncocross Australia Pty Ltd.** · enrollment: 23 (actual)

## Conditions studied

- Cancer Cachexia

## Interventions

- **DRUG:** OC514 (Low dose)
- **DRUG:** OC514 (Mid dose)
- **DRUG:** OC514 (High dose)
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05264038
- **Lead sponsor:** Oncocross Australia Pty Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-03
- **Primary completion:** 2022-09-07
- **Final completion:** 2023-03-13
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2023-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05264038

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05264038, "A First in Human Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics Effects of OC514". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05264038. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*